Storia in 5 fonti

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

AstraZeneca and Daiichi Sankyo have secured approval from the US FDA for Datroway (datopotamab deruxtecan) to treat metastatic TNBC.

Raccontata damorningstar.comendpoints.newsfiercepharma.compharmaceutical-technology.commedpagetoday.com

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

pharmaceutical-technology.comStai leggendo2 g fa

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

AstraZeneca and Daiichi Sankyo have secured approval from the US FDA for Datroway (datopotamab deruxtecan) to treat metastatic TNBC.

originale

endpoints.news5 g fa

FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval

The FDA has approved the TROP2-directed ADC Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor Gilead.

Leggi questa versione → originale

morningstar.com5 g fa

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of…

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

Leggi questa versione → originale

fiercepharma.com5 g fa

AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and Daiichi Sankyo's…

Leggi questa versione → originale

medpagetoday.com1 g fa

New First-Line Option Approved in Triple-Negative Breast Cancer

Datopotamab deruxtecan indicated for patients ineligible for immunotherapy

Leggi questa versione → originale

Timeline cronologica

1. venerdì 22 maggio 2026·morningstar.com
   

   Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple…

   Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not…

2. venerdì 22 maggio 2026·endpoints.news
   

   FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval

   The FDA has approved the TROP2-directed ADC Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor…

3. venerdì 22 maggio 2026·fiercepharma.com
   

   AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

   The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is…

4. lunedì 25 maggio 2026·pharmaceutical-technology.com
   

   AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

   AstraZeneca and Daiichi Sankyo have secured approval from the US FDA for Datroway (datopotamab deruxtecan) to treat metastatic TNBC.

5. martedì 26 maggio 2026·medpagetoday.com
   

   New First-Line Option Approved in Triple-Negative Breast Cancer

   Datopotamab deruxtecan indicated for patients ineligible for immunotherapy